A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions

Hepatic Impairment

Interventions

DRUG

Omaveloxolone 50 mg capsules

Capsules containing 50 mg of omaveloxolone

Trial Locations (3)

Orlando Clinical Research Center, Orlando

Clinical Pharmacology of Miami, LLC, Miami

Orange County Research Center, Tustin